Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRODIGE 113 – REWENEC-01
2024-519922-19-00Phase 2Withdrawn
- Sponsor
- Hospices Civils de Lyon
- Start
- Feb 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial in gastroenteropancreatic neuroendocrine carcinoma (GEP-NEC) and neuroendocrine carcinoma (NEC) comparing FOLFIRI + zimberelimab + domvanalimab with FOLFIRI control (hybrid synthetic control) (2 arms). Primary endpoint: overall survival. Planned start Feb 2026; status: withdrawn.
02
Drugs
zimberelimabdomvanalimabFOLFIRI
03
Conditions
gastroenteropancreatic neuroendocrine carcinoma (GEP-NEC)neuroendocrine carcinoma (NEC)
Beyond the preview
Go deeper on 2024-519922-19-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-519922-19-00.